Moreover, FTY720 promoted toxic effects in different B-cell malignancies and B-cell from chronic lymphocytic leukemia (CLL) patients through activating PP2a and dephosphorylating of ERK1/2 (85). Here, MAPK3 is linked to B-cell chronic lymphocytic leukemia.